Management of congenital diaphragmatic hernia

Congenital diaphragmatic hernia (CDH) has an incidence of between one in 2000–5000 live births. The hidden mortality associated with CDH includes spontaneous abortions and stillbirths as well as therapeutic abortions (often for other identified anomalies). The management of CDH has been intensely debated since Ladd and Gross stated in 1940 that early surgery was the proper treatment for these patients. Controversies have surrounded ideal preoperative management, timing of surgery, and indeed whether surgery should be offered to all. Despite the advances in neonatal care, inroads into mortality which might have been anticipated have not materialised and it remains relatively unchanged at 40–50%. However, we now stand on the threshold of an exciting stage in the development of neonatal cardiorespiratory support. The role of new therapeutic modalities such as extracorporeal membrane oxygenation (ECMO), surfactant, high frequency ventilation (HFV), inhaled nitric oxide (iNO), in utero interventions, and liquid ventilation have intensified the debate.

Antenatal management

Prenatal diagnostic rates vary from 10–90% depending on local antenatal ultrasound screening protocols. Prenatal diagnosis allows for counselling of parents and planned management but does not predict outcome. Prenatal diagnosis of CDH should lead to careful inspection for other major anomalies and chromosomal analysis is justified. Laterality, presence of liver and stomach in chest, left ventricular mass, presence of polyhydramnios, and ultrasound indices of relative lung volume have been used in attempts to predict outcome, but are not reliable. Only the presence of associated major anomalies is reliably associated with a poor prognosis.

IN UTERO SURGERY

To date, a number of surgical approaches have been attempted. After careful preparatory animal studies, Harrison et al repaired the defect by fetal surgery. Results were disappointing as the technique could only be used in those without liver herniation. Even with technical success, there was a poor outcome because of preterm labour. Based on the observation that an obstructed trachea prevents the development of lung hypoplasia, a number of techniques have been devised on the “plug the lung until it grows” principle. These include a variety of tracheal plugs and tracheal clipping at fetoscopy. Encouraging results have been reported in experimental settings. Clinical results are preliminary but there remain many obstacles. Premature labour is a major problem with all in utero techniques. Outcomes have been generally disappointing.

PERINATAL CARE

Close liaison between the fetal medicine/obstetric, neonatal, and surgical teams is essential. The infant with prenatal diagnosis of CDH should be delivered in an institution with full facilities and a management strategy. Antenatal glucocorticoid administration, now standard practice in the prevention of respiratory distress syndrome after premature labour, has been shown to improve pulmonary immaturity in rats with experimentally induced CDH and a small study using low dose dexamethasone and thyrotrophin releasing hormone showed benefit in patients. A larger, prospective study is needed. Senzaki and colleagues have proposed the administration of morphine and pancuronium in the perinatal period to prevent the proposed enlargement of the hernia and mediastinal deviation caused by spontaneous breathing just after birth as an adjunct to immediate perinatal management.

The EXIT technique, whereby the baby is delivered through the hysterotomy at caesarean section, allows interventions such as immediate intubation and delivery of surfactant before the first breath to be undertaken while the fetus is partially delivered but still supported by the placental circulation. This is an approach presently being evaluated.

Postnatal management

The major underlying problems in CDH are pulmonary hypoplasia and high pulmonary vascular resistance which cause right-to-left shunting of blood away from the lungs and failure of adaptation to extrauterine life. This leads to hypoxia, hypercarbia, and acidosis, all of which exacerbate pulmonary hypertension. Management strategies are structured to optimise gas exchange and to reduce pulmonary hypertension while minimising ventilator induced lung damage.

IMMEDIATE CARE

A high index of suspicion is necessary to establish postnatal diagnosis. The presence of a scaphoid abdomen, deviation of the heart beat, and unilateral diminished breath sounds in the presence of respiratory distress prompt the diagnosis. The infant should be intubated immediately after birth. It is important to avoid mask ventilation which will exacerbate respiratory embarrassment. A large bore gastric tube (minimum 10 FG) is passed to decompress the intrathoracic intestine. Contralateral pneumothorax is a recognised complication of over vigorous resuscitation.

VENTILATION STRATEGIES

Gentle ventilation is critical and conventional ventilator parameters should be set to minimise barotrauma in a setting of bilateral hypoplastic, delicate lungs. The aim is to achieve adequate oxygenation with the lowest possible pressures. Data from preductal and postductal saturation monitors and a preductal arterial line should be used to optimise ventilation. A preductal pH ≥ 7.20 and an arterial oxygen pressure of ≥ 6.5 kPa (with an oxygen saturation of 85–90%) should be accepted. Permissive hypercapnia will reduce ventilation induced lung damage. Excessive ventilation parameters should not be used in an attempt to normalise blood gas results. A cardiac echo will demonstrate a persistent patent ductus arteriosus and determine ductal flow. Alternative strategies may be necessary to minimise the right-to-left shunt. Adequate analgesia and
sedation is essential. Most centres use muscle relaxants though a number advocate awake ventilation using patient triggered ventilation techniques. Attention to fluid balance should ensure adequate perfusion of tissues without causing pulmonary overload.

HIGH FREQUENCY VENTILATION
HFV, either initially or when conventional ventilation proves ineffective, is an attractive approach to optimise alveolar recruitment and reduce barotrauma. Most experience is of oscillatory ventilation (HFOV). The rationale is that small tidal volumes and gas transport by augmented diffusion, results in lower shear stresses and less barotrauma. Better alveolar recruitment with HFOV may also be beneficial in delivering iNO to the pulmonary resistance vessels. The place of HFOV in CDH is uncertain and prospective studies are needed.

INTRATRACHEAL PULMONARY VENTILATION (ITPV)
ITPV is an ingenious technique developed by Theodore Kolobow, where a high gas flow is introduced into the trachea just above the carina in a reverse direction via an ultrathin endotracheal tube. It allows for excellent carbon dioxide removal and very low intratracheal ventilation pressures. Experience is very limited to date. INTRAVASCULAR VASODILATOR AGENTS
The search for a specific pulmonary vasodilator has so far been unrewarding. Tolazoline has histamine-like action as well as being an adrenergic antagonist with cholinomimetic properties. It has no place in the management of CDH. Magnesium sulphate has had some reported success. It lowers smooth muscle intracellular calcium and may inhibit vasoconstriction. Prostacycline acts via cGMP and also lowers intracellular calcium. It has the disadvantage of platelet inactivation. All intravascular agents cause variable systemic hypotension. An inotrope such as dopamine may be needed to augment systemic pressure.

INHALED NITRIC OXIDE
Inhaled NO allows selective pulmonary vasodilatation. It has been shown to reduce the need for ECMO support in appropriate infants with persistent pulmonary hypertension of the newborn. Its value in the infant with CDH is less clear. Concern has been expressed over potential side effects. Its use leads to a reduction in endogenous production of NO, and in selected infants with CDH the response and benefit may be temporary.

SURFACTANT
Experimental studies have revealed biochemical immaturity in association with CDH. However, amniotic fluid analysis has not proved an indicator of surfactant deficiency in the human fetus. Administration of surfactant in experimental conditions and in neonates has revealed the best initial benefit. There continues to be the problem of inadequate quantity, distribution, and inactivation of surfactant in CDH. It may need to be administered prophylactically, before the first breath.

EXTRACORPOREAL MEMBRANE OXYGENATION
The utilisation of partial cardiorespiratory bypass allows for lung rest and reduction in pulmonary vascular resistance. Data from the Extracorporeal Life Support Organization (ELSO) from January 1997 on over 2450 cases reported 59% survival for neonates with CDH receiving ECMO support. In the UK Collaborative Neonatal ECMO Trial ECMO was significantly better than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management, though less good than conventional management.
Follow up
Survivors can have a range of problems. Failure to thrive is a feature of many survivors of CDH. Gastro-oesophageal reflux and oesophageal dismotility are common after CDH repair. Gastro-oesophageal reflux tends to be refractory to medical treatment and may require surgical management. Most survivors have adequate respiratory function, though long term ventilation has been associated with bronchopulmonary dysplasia. Some patients have thoracic deformities severe enough to warrant corrective surgery in later life. Neurodevelopmental outcome generally reflects the severity of illness and in this regard sensorineural deafness needs to be considered.

The future
The principle of gentle ventilation aimed at preventing ventilation induced lung injury is well established. Surgical repair will be delayed while the reactivity of the pulmonary vasculature is manipulated. Antenatal maternal glucocorticoid/thyrotrophin releasing hormone prophylaxis will be included in protocols if studies confirm benefit in the fetus with CDH. There may be a place for prophylactic surfactant, given at delivery before the first breath. Better antenatal diagnosis and more accurate indicators of the high risk fetus with CDH who might benefit from fetal intervention will hopefully occur. As technical problems are overcome and effective control of preterm labour be perfected, fetoscopic intervention may be the ultimate optimal management for the high risk antenatally diagnosed CDH.

The role of iNO will be clarified by trials, safety profiles will be determined, and optimal delivery protocols will be defined. Research continues into other mediators of pulmonary resistance vessels. Recently, there has been interest in the role of 5-hydroxytryptamine and the vasoconstrictor peptide endothelin-1 in the pathophysiology of pulmonary hypertension. Specific cell surface receptor antagonists to these substances in the lung vasculature may play a part in the reversal of pulmonary hypertension in CDH.

Venovenous ECMO, possibly in conjunction with perfluorocarbon induced lung distension, may be the optimal approach for infants with CDH who do not respond to less invasive management.

C F DAVIS
A J SABHARWAL
Department of Surgical Paediatrics,
Royal Hospital for Sick Children,
Yorkhill, Glasgow G3 8SF